ClinicalTrials.gg
RecruitingNCT05288777Breast53Updated Apr 18, 2025

Adjuvant Chemoradiation and Biomarkers of Response in High-risk Breast Cancer

A Phase 2/3 interventional study of T-DM1 and Capecitabine in Breast Cancer, Breast Cancer Stage I and Breast Cancer Stage II, sponsored by University of Virginia. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-04-18.

Sponsored by University of Virginia · Phase 2/3, Interventional, and Treatment

How we know · 5 judgments

From the registry’s dates

  • Started Jul 2022; still recruiting 4 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
45
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 56 studies testing Ado-Trastuzumab Emtansine in Breast Neoplasms — 11 open to participants now, 16 under way, 2 of them phase 3. Ado-Trastuzumab Emtansine · Breast Neoplasms.

Planned enrollment
41st of 56
45 · median 103
Started
2022
with 1 other
Phase 2/3
2 of 56
1 open now
Primary completion
2028-12
later than 12 of 15 live
Registered
48th of 56
by date

Among the 56 studies testing Ado-Trastuzumab Emtansine in Breast Neoplasms, this one is the 41st largest by planned enrollment, is one of 2 that started in 2022, is one of 2 in phase 2/3, reaches primary completion later than 12 of the 15 other live ones, and was the 48th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

11 of the 56 studies testing Ado-Trastuzumab Emtansine in Breast Neoplasms are open now, in 7 countries. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 11 open studies →

About Ado-Trastuzumab Emtansine

Ado-Trastuzumab Emtansine: first FDA approval 2013 (KADCYLA), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 56 studies testing Ado-Trastuzumab Emtansine in Breast Neoplasms, or all of them as a file.
02

Study summary

The goal of this study is to evaluate the safety and effectiveness of adjuvant chemoradiation therapy in high-risk breast cancer patients who had received neoadjuvant chemotherapy before their lumpectomy and/or mastectomy and were found to have residual disease. As well as examine the effects of this treatment combination on the immune system.

Read the detailed description

Breast cancer is often treated with a combination of surgery, chemotherapy and radiation. In patients with advanced breast cancer, (neoadjuvant) chemotherapy is often given prior to surgical removal (lumpectomy and/or mastectomy). Neoadjuvant chemotherapy has been consistently shown to down-stage primary breast tumors and convert positive underarm lymph nodes to pathologically negative nodes. Residual disease discovered after receiving neoadjuvant chemotherapy indicates an increased risk for recurrence and poor overall survival. The combination of concurrent chemotherapy and radiation after surgery (adjuvant chemoradiation) may improve local and distant recurrence outcomes in high risk breast cancer patients. Chemoradiation is a standard treatment for many cancers and is universally associated with improvements in local recurrence, however, it has not historically been given as post-surgery breast cancer treatment.

The study will evaluate the safety, feasibility, and effectiveness of chemoradiation therapy in high-risk breast cancer patients. Radiation has been associated with various effects on immune cells. The study will also examine the effects of this combination on the immune cells.

Participants on this trial will be treated (per approved clinical guidelines) with capecitabine or Trastuzumab emtansine (T-DM1) depending on Her2 status while receiving radiation at the same time. Participants will have their blood drawn at various timepoints during treatment and follow up. Participants will also be asked to complete surveys asking about overall health and wellbeing.

03

Conditions studied

  • Breast Cancer
  • Breast Cancer Stage I
  • Breast Cancer Stage II
  • Breast Cancer Stage III

Browse trials for

Keywords

  • Radiation
  • Chemoradiation
  • Chemotherapy
  • Chemo
  • T-DM1
  • xeloda
  • capecitabine
  • Adjuvant
  • Combination treatment
  • trastuzumab
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Provision of signed and dated form
  2. Stated willingness to comply with all study procedures and availability for the duration of the study
  3. Male or female, aged 18 or older
  4. Diagnosis of stage I-IIIB breast cancer
  5. Received chemotherapy (minimum of 3 cycles) and surgical resection (lumpectomy and/or mastectomy)
  6. Discovered to have residual disease at least ypT1aNx or ypTxN1mic at surgical resection
  7. Candidate for adjuvant chemoradiation as part of standard clinical care
  8. Planned initiation of radiation within 12 weeks of their final oncologic surgery
  9. performance status ≤2
  10. Adequate cardiac function, with greater or equal to 45% (only for patients who will receive TDM-1 therapy)
  11. Adequate organ function per the following criteria within 21 days before the start of treatment. If a laboratory value required for study eligibility does not meet the below requirements, the value may be retested.

    • ≥1.5 k/uL
    • ≥100 k/uL
    • ≥ 10 g/dL
    • Serum Creatinine ≤ 1.5 x
    • ≤ 1.5 x ULN (except in patients with Gilbert's disease, where bilirubin to 4x ULN is allowed).
    • and ALT ≤ 2.5 x ULN
    • Alkaline phosphatase ≤ 2.5 x ULN
  12. For females and males of : agreement to use adequate during study participation and for an additional 6 months after the end of chemoradiation administration or until advised by their medical oncologist
  13. Agreement to adhere to Lifestyle Considerations throughout study duration
  14. Subjects taking warfarin and plan to receive capecitabine will need their anticoagulant management assessed before starting treatment.

Exclusion criteria

Exclusion Criteria:

  1. Had a mastectomy with expander placement or immediate reconstructions
  2. Diagnosed with systemic lupus
  3. Diagnosed with scleroderma
  4. Diagnosed with a genetic mutation associated with increased sensitivity to radiation (e.g. ataxia-telangectasias (AT)). AT heterozygotes without known radiation sensitivity may be included.
  5. Acute bacterial or fungal infection requiring intravenous antibiotics at time of registration.
  6. Pathologic evidence of disease, or strong clinical/radiological evidence of metastatic disease, at the investigator's judgment.
  7. Pregnancy or lactation
  8. Incarceration
  9. Presence of cardiac pacemaker on side of the body that is being treated unless the pacemaker can be moved prior to treatment.
  10. Anthracycline exposure exceeding a cumulative doxorubicin dose of 264 mg/m2 (240 mg/m2 plus a 10% threshold)
  11. Known allergic reactions to components of capecitabine or T-DM1
  12. Known DPD deficiency for patients prescribed capecitabine
  13. Febrile illness within a week of starting treatment
  14. Incomplete healing of chest wall or breast in the treatment field within 12 weeks from surgery.
  15. Known or active hepatitis.
  16. Unwilling to discontinue endocrine therapy if currently taking endocrine therapy.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
45 participants (estimated)

Study arms

  • Other
    Her2/neu positive and lymph node positive

    T-DM1/ trastuzumab emtansine infusion along with radiation to the breast or chest wall and lymph nodes

    Drug: T-DM1 · Radiation: External Beam Radiation Therapy 1

  • Other
    Her2/neu positive and lymph node negative

    T-DM1/trastuzumab emtansine infusion along with radiation to the whole breast or chest wall

    Drug: T-DM1 · Radiation: External Beam Radiation Therapy 0

  • Other
    Her2/neu negative and lymph node positive

    oral capecitabine twice per day along with radiation to the breast or chest wall and lymph nodes

    Drug: Capecitabine · Radiation: External Beam Radiation Therapy 1

  • Other
    Her2/neu negative and lymph node negative

    oral capecitabine twice per day along with radiation to the whole breast or chest wall

    Drug: Capecitabine · Radiation: External Beam Radiation Therapy 0

Interventions

  • DrugAdo-Trastuzumab EmtansineStudies of Ado-Trastuzumab EmtansineAdo-Trastuzumab Emtansine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Dosed at 3.6 mg/kg of body weight every 3 weeks for Her2/neu+ patients for a total duration of 14 cycles.

    Also known as: trastuzumab emtansine

  • Dosed at 825 mg/m2 +/- 150mg twice per day for a total duration of 6 months

    Also known as: xeloda

  • RadiationExternal Beam Radiation Therapy 0

    Dose of 40 Gy in 15 fractions to the whole breast or chest wall followed by consideration of a 10 Gy in 4 fraction boost to the lumpectomy cavity for a total duration of 15-19 days. Internal mammary nodal, dissected axilla coverage, and boost will be at the radiation oncologist's discretion.

    Also known as: EBRT

  • RadiationExternal Beam Radiation Therapy 1

    Dose of 40 Gy in 15 fractions to either the breast or chest wall along with comprehensive nodal radiation followed by consideration of a 10 Gy in 4 fraction boost for a total duration of 15-19 days. Internal mammary nodal, dissected axilla coverage, and boost will be at the radiation oncologist's discretion.

    Also known as: EBRT

06

What researchers measure

Primary outcomes

  1. Assess safety via toxicity grading

    Assessment of toxicity frequency and severity using CTCAE v5.0 adverse event grading scale throughout chemoradiation treatment and follow up.

    Time frame: 1 year

  2. Assess feasibility via treatment delays and completion

    Percent of participants completing adjuvant chemoradiation therapy and percent of participants requiring radiation or chemotherapy dose delays.

    Time frame: 1 year

Secondary outcomes

  1. Assess chronic cosmetic outcomes via LENT-SOMA scale

    Assessment of chronic radiation-related cosmetic outcomes (e.g. dermatitis, telangiectasia, pigmentation, and radiation fibrosis) using "Late Effects Normal Tissue Task Force (LENT)-Subjective, Objective, Management, Analytic (SOMA)" scale throughout chemoradiation treatment and follow up. Each side effect is graded on a scale of 0 to 4, with higher scores meaning more severe outcome.

    Time frame: 1 year

  2. Assess acute cosmetic outcomes via RTOG/EORTC scale

    Assessment of overall acute radiation related skin changes using the "Toxicity Criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC)" grading scale throughout chemoradiation treatment and follow up. Each side effect is graded on a scale of 0 to 4, with higher scores meaning more severe outcome.

    Time frame: 1 year

  3. Assess cosmetic outcomes via breast measurements

    Measurement of breast tissue size by measuring tape/ruler.

    Time frame: 1 year

Other outcomes

  1. Estimate recurrence-free survival

    Recurrence-free survival after 1 year of adjuvant chemoradiation therapy.

    Time frame: 1 year

  2. Describe the amount and type of immune cells via lab tests

    Lab analysis (CBC w/ Differential and ELISA assays) of blood to characterize and count leukocyte populations (neutrophils, monocytes, lymphocytes) throughout adjuvant chemoradiation treatment and follow up.

    Time frame: 1 year

  3. Assess quality of life via RAND SF-36 patient survey

    RAND SF-36 survey assesses feelings on overall health and activity level during follow up after adjuvant chemoradiation treatment.

    Time frame: 1 year

  4. Assess quality of life via FACT-B patient survey

    Functional Assessment of Cancer Therapy- Breast (FACT-B) survey generally assess physical wellbeing, Social wellbeing, emotional wellbeing and functional well being during follow up after adjuvant chemoradiation treatment.

    Time frame: 1 year

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2022 (actual). Primary completion is estimated for Dec 2028, 77 months after the start.

Of 43 non-industry phase 2/3 interventional studies under Breast Neoplasms, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 91. This study's planned 77 months is above that.

Counting every sponsor, half of 56 studies reached it within 57 months; a quarter within 32 and three quarters within 88.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 24, 2022
First posted
Mar 21, 2022
StartActual
Jul 11, 2022
Primary completionEst.
Dec 2028
CompletionEst.
Dec 2029
Last update
Apr 18, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05288777
Responsible party
Einsley-Marie Janowski, MD (Assistant Professor, University of Virginia) — Principal investigator
First posted
Mar 21, 2022
Start date
Jul 11, 2022
Primary completion
Dec 2028 (estimated)
Completion
Dec 2029 (estimated)
Last update
Apr 18, 2025

Study contacts

Song Wood
Contact
stw2g@hscmail.mcc.virginia.edu
4342430008
Einsley Janowski, MD, PhD
principal investigator · University of Virginia

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ado-Trastuzumab Emtansine · Capecitabine

Start the discussion